Unlike tech investing, where a single power-law outlier can return the entire fund, biotech wins are smaller in magnitude. This dynamic forces biotech VCs to prioritize a higher success rate across their portfolio rather than solely hunting for one massive unicorn.

The primary risk to a VC fund's performance isn't its absolute size but rather a dramatic increase (e.g., doubling) from one fund to the next. This forces firms to change their strategy and write larger checks than their conviction muscle is built for.

A smaller fund size enables investments in seemingly niche but potentially lucrative sectors, such as software for dental labs. A larger fund would have to pass on such a deal, not because the founder is weak, but because the potential exit isn't large enough to satisfy their fund return model.

Resist the common trend of chasing popular deals. Instead, invest years in deeply understanding a specific, narrow sector. This specialized expertise allows you to make smarter investment decisions, add unique value to companies, and potentially secure better deal pricing when opportunities eventually arise.

The focus on AI among institutional investors is so absolute that promising non-AI companies risk "dying of neglect" and being unable to secure follow-on funding. This creates a potential opportunity gap for angel investors to fund valuable businesses in overlooked sectors.

The venture capital return model has shifted so dramatically that even some multi-billion-dollar exits are insufficient. This forces VCs to screen for 'immortal' founders capable of building $10B+ companies from inception, making traditionally solid businesses run by 'mortal founders' increasingly uninvestable by top funds.

VC outcomes aren't a bell curve; a tiny fraction of investments deliver exponential returns covering all losses. This 'power law' dynamic means VCs must hunt for massive outliers, not just 'good' companies. Thiel only invests in startups with the potential to return his whole fund.

Seed funds that primarily act as a supply chain for Series A investors—optimizing for quick markups rather than fundamental value—are failing. This 'factory model' pushes them into the hyper-competitive 'white hot center' of the market, where deals are priced to perfection and outlier returns are rare.

VCs are incentivized to deploy large amounts of capital. However, the best companies often have strong fundamentals, are capital-efficient, or even profitable, and thus don't need to raise money. This creates a challenging dynamic where the best investments, like Sequoia's investment in Zoom, are the hardest to get into.